HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hassan Jomaa Selected Research

fosmidomycin

5/2011Fosmidomycin uptake into Plasmodium and Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways.
2/2011NMR studies of DOXP reductoisomerase and its inhibitor complex.
9/2007Synthesis and evaluation of alpha,beta-unsaturated alpha-aryl-substituted fosmidomycin analogues as DXR inhibitors.
9/2007Novel deoxyxylulosephosphate-reductoisomerase inhibitors: fosmidomycin derivatives with spacious acyl residues.
1/2007Isoprenoid biosynthesis of the apicoplast as drug target.
8/2006Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria.
9/2005Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria.
11/2004Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria.
3/2004Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children.
6/2003Fosmidomycin for the treatment of malaria.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hassan Jomaa Research Topics

Disease

17Malaria
01/2016 - 09/2002
7Falciparum Malaria (Plasmodium falciparum Malaria)
06/2007 - 09/2002
6Infections
10/2009 - 02/2003
4Body Weight (Weight, Body)
08/2006 - 03/2004
3Bacterial Infections (Bacterial Infection)
02/2011 - 06/2003
2Necrosis
05/2009 - 06/2002
2Fever (Fevers)
01/2007 - 09/2005
2Neutropenia
08/2006 - 09/2005
1Tuberculosis (Tuberculoses)
08/2013
1Disease Progression
10/2009
1Neoplasms (Cancer)
10/2009
1Acquired Immunodeficiency Syndrome (AIDS)
10/2009
1Hemorrhage
05/2009
1Multiple Sclerosis
05/2007
1Communicable Diseases (Infectious Diseases)
04/2007

Drug/Important Bio-Agent (IBA)

13fosmidomycinIBA
05/2011 - 09/2002
6Antimalarials (Antimalarial Agents)IBA
01/2016 - 09/2002
4Interleukin-2 (IL2)IBA
08/2013 - 06/2002
4Mevalonic Acid (Mevalonate)IBA
11/2008 - 06/2003
4Clindamycin (Cleocin)FDA LinkGeneric
06/2007 - 03/2004
33- (N- acetyl- N- hydroxy)aminopropylphosphonic acidIBA
01/2016 - 07/2005
3Terpenes (Terpenoids)IBA
11/2008 - 06/2003
2Pharmaceutical PreparationsIBA
05/2011 - 11/2003
2Farnesyltranstransferase (Farnesyltransferase)IBA
08/2008 - 01/2004
2EnzymesIBA
09/2007 - 06/2003
2interleukin-21 (interleukin 21)IBA
04/2007 - 06/2002
1Glucose (Dextrose)FDA LinkGeneric
05/2009
12-C-methylerythritol 4-phosphateIBA
11/2008
1Phosphates (Orthophosphate)IBA
09/2007
1Interferon-betaIBA
05/2007
1Chemokine CXCL13IBA
04/2007
14-hydroxy-3-methylbut-2-enyl pyrophosphateIBA
04/2007
14-hydroxy-3-methyl-2-butenyl diphosphateIBA
04/2007
1Antiparasitic Agents (Antiparasitics)IBA
08/2006
1Hemoglobins (Hemoglobin)IBA
08/2006
1ArtesunateIBA
09/2005
1Organophosphonates (Phosphonates)IBA
07/2005
1EstersIBA
07/2005
1ProdrugsIBA
07/2005
1Chloroquine (Aralen)FDA LinkGeneric
11/2003
11-deoxy-D-xylulose 5-phosphate reductoisomeraseIBA
06/2003
1Anti-Bacterial Agents (Antibiotics)IBA
06/2003
1XyluloseIBA
06/2003
1Interleukin-15 (Interleukin 15)IBA
06/2002
1Interferon-gamma (Interferon, gamma)IBA
06/2002
1CytokinesIBA
06/2002
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2002

Therapy/Procedure

2Therapeutics
10/2009 - 05/2007